z-logo
open-access-imgOpen Access
Feeding Dietary Mannan Oligosaccharides to Juvenile Nile Tilapia, Oreochromis niloticus , Has No Effect on Hematological Parameters and Showed Decreased Feed Consumption
Author(s) -
Sado Ricardo Yuji,
Bicudo ÁLvaro José De Almeida,
Cyrino José Eurico Possebon
Publication year - 2008
Publication title -
journal of the world aquaculture society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 60
eISSN - 1749-7345
pISSN - 0893-8849
DOI - 10.1111/j.1749-7345.2008.00219.x
Subject(s) - nile tilapia , oreochromis , biology , mannan , zoology , juvenile , tilapia , feed conversion ratio , food science , body weight , fishery , fish <actinopterygii> , ecology , endocrinology , biochemistry , polysaccharide
Impaired immune system by environmental stressors can lead fishes to be more susceptible to diseases that limit the economic development of aquaculture systems. This study was set out to determine the effect of six levels of mannan oligosaccharides (MOS; ActiveMOS ® ; Biorigin, Lençois Paulista,São Paulo, Brazil) on the performance index and hematology of Nile tilapia, Oreochromis niloticus juveniles. Fish (13.62 g) were randomly distributed into 18 plastic aquaria (300 L; 20 fishes per aquarium) and fed during 45 d with a commercial diet supplemented with 0, 0.2, 0.4, 0.6, 0.8, and 1% dietary MOS, in a totally randomized design trial ( n   =   3); biometrical and hematological data were collected and analyzed. There were no significant differences in hematological parameters between fish fed control and MOS supplementation diets, and daily feed consumption (FC) decreased ( P  < 0.05) with increasing levels of dietary MOS. Dietary MOS did not increase leukocyte count and presented negative effects on FC of Nile tilapia. At 0.4% MOS supplementation, the individual weight gain was higher in absolute values but not different ( P  > 0.05) compared to control diet.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here